Analysis of tumor microenvironment alterations in partially responsive rectal cancer patients treated with neoadjuvant chemoradiotherapy

Purpose Achieving a pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (NCRT) remains a challenge for most patients with rectal cancer.

Exploring the potential of combining NCRT with immunotherapy or targeted therapy for those achieving a partial response (PR) offers a promising avenue to enhance treatment efficacy.

This study investigated the impact of NCRT on the tumor microenvironment in locally advanced rectal cancer (LARC) patients who exhibited a PR.

Methods This was a retrospective, observational study.

Five patients demonstrating a PR after neoadjuvant treatment for LARC were enrolled in the study.

Biopsy samples before treatment and resected specimens after treatment were stained with a panel of 26 antibodies targeting various immune and tumor-related markers, each labeled with distinct metal tags.

The labeled samples were then analyzed using the Hyperion imaging system.

Results Heterogeneity within the tumor microenvironment was observed both before and after NCRT.

Notably, tumor-associated macrophages, CD4 + T cells, CD8 + T cells, CD56 + natural killer cells, tumor-associated neutrophils, cytokeratin, and E-cadherin exhibited slight increase in abundance within the tumor microenvironment following treatment (change ratios = 0.78, 0.2, 0.27, 0.32, 0.17, 0.46, 0.32, respectively).

Conversely, the number of CD14 + monocytes, CD19 + B cells, CD45 + CD4 + T cells, collagen I, α-smooth muscle actin, vimentin, and β-catenin proteins displayed significant decreases post-treatment (change ratios = 1.73, 1.92, 1.52, 1.25, 1.52, 1.12, 2.66, respectively).

Meanwhile, Foxp3 + regulatory cells demonstrated no significant change (change ratio = 0.001).

Conclusions NCRT has diverse effects on various components of the tumor microenvironment in LARC patients who achieve a PR after treatment.

Leveraging combination therapies may optimize treatment outcomes in this patient population.